| |
|
|
|
Nymox Pharmaceutical Corporation  
|
|
2.09 0.09 (0.04%) |
04-18 16:00 |
|
Open: |
2.06 |
Pre close: |
2 |
Target:
|
2.53
|
|
High: |
2.18 |
Low: |
1.93 |
Resistance:
|
2.17
2.41
|
|
Volume: |
191,863 |
Market Cap: |
141M |
Support:
|
1.78
1.48
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
1.92
 |
MACD |
MACD(12,26):
|
-0.05 |
|
MA(20): |
2.04  |
Signal(12,26,9): |
-0.04 |
|
MA(100): |
1.98 |
Stochastic Oscillator |
%K(14,3):
|
49.61 |
|
MA(250): |
2.57 |
%D(3): |
28.50 |
|
Average Volume(K) |
3-Month: |
8657
|
52-Week |
High:
|
4.35 |
|
10-Days: |
11435 |
Low: |
1.25 |
|
RSI |
RSI(14):
|
52.36 |
Change(%): |
-50.1 |
|
Financials, Statistics and Valuation |
|
EPS |
0.000 |
Return on Equity (ttm) |
-365.0 |
Shares Out. (M) |
64.68 |
|
EPS Est. Current Year |
-0.200 |
Return on Assets (ttm) |
-235.1 |
Shares Float (M) |
37.86 |
|
EPS Est. Next Year |
-0.570 |
PEG Ratio |
0.00 |
% Held by Insiders |
0.00 |
|
EPS Est. Next Quarter |
0.000 |
Qtrly Rev. Growth |
-81.9 |
% Held by Institutions |
11.80 |
|
Forward EPS |
1.#IO |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
0 |
|
Book Value (p.s.) |
19.120 |
EBITDA (p.s.) |
0.000 |
P/E |
0.00 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
0.11 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-7.80 |
P/S |
0.00 |
|
Operating Margin |
-3558.86 |
Levered Free Cash Flow
(M) |
-3.91 |
P/CF |
-17.33 |
|
|
|
|
|
|
